Talking the Cure by Hogan Lovells
Hogan Lovells is always thinking about how to conquer and foresee the most significant industry issues facing our clients. If you’ve been following us for the past two years, you’ve heard first-hand from our lawyers around the world on significant developments in the Life Sciences & Health Care sector and why they are so passionate about the industry. In season 3, we’ll unpack new and exciting industry trends and bring you more outside perspectives to keep you ahead of the curve.
Episodes
Episodes
Monday Oct 12, 2020
Monday Oct 12, 2020
In this episode, Arne Thiermann and Dr. Julian Braun, director of legal at Heartbeat Labs, discuss the opportunities and risks for international companies planning to enter the German market in the digital health sector, especially with regard to reimbursement and the impact of regulatory changes in Germany.
Monday Oct 12, 2020
Monday Oct 12, 2020
In this episode, May Lyn Yuen and Hein Van den Bos discuss the balance of innovation in drug development, the competitive aspects and affordability of medicines in Europe, and the changes in the regulatory environment at the EU level as well as the EU Member State level.
Monday Oct 12, 2020
Monday Oct 12, 2020
In our latest episode, you will get to know members of our Science Unit Dr. Marion Palmer and Dr. Rachel Gribben, who talk about their experience working in this unit for over 20 years, as well as their latest work on COVID-19 related matters. We also discuss how they are providing pro bono work and what they do to relax.
Monday Oct 12, 2020
Monday Oct 12, 2020
In this episode, our partners Brooke Bumpers and William Ferreira talk about the growth of the telehealth industry during the COVID-19 pandemic and the opportunities and challenges for companies and providers in the United States and internationally. We also discuss how providers and patients are reacting to the increased use of telehealth.
Monday Oct 12, 2020
Talking The Cure: Exploring the industry with Philip Katz - Part 2
Monday Oct 12, 2020
Monday Oct 12, 2020
In the second part of our two-part interview with Philip Katz, head of the Hogan Lovells Pharmaceuticals and Biotechnology Regulatory Practice, we discuss team management, diversity and we also get to learn about Phil, when he shuts down his blackberry. We had a lot to cover in our conversation with Phil, so if you haven't checked out yet, listen to the first part of our conversation.
Monday Oct 12, 2020
Talking The Cure: Exploring the industry with Philip Katz - Part 1
Monday Oct 12, 2020
Monday Oct 12, 2020
In the first episode of our two-part interview with Philip Katz, head of the Hogan Lovells Pharmaceuticals and Biotechnology Regulatory Practice, we discuss developments in the pharmaceuticals and biotechnology industry, the global practice of law in this space, and we also get to learn about Phil and his career journey. We had a lot to cover in our conversation with Phil, so stay tuned for more industry insights in part two of our interview!
Monday Oct 12, 2020
Monday Oct 12, 2020
In this episode, our partners Jörg Schickert and Nikolas Zirngibl talk with Jörn Bungartz, an adviser in the digital health sector, about opportunities and barriers for venture capital in the life sciences and health care industry in Germany.
You can find additional thought leadership and information regarding venture capital in the life sciences and health care industry on HL Engage.
If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.
Monday Oct 12, 2020
Talking The Cure: Discussing European developments on Covid-19
Monday Oct 12, 2020
Monday Oct 12, 2020
In this episode, Elisabethann Wright, Jane Summerfield, and Hein Van den Bos talk about developments in Belgium, the UK, and the Netherlands and how the Covid-19 pandemic impacts clinical trials and the authorization process of the local authorities.